Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-004635
Filing Date
2025-01-21
Accepted
2025-01-21 06:02:06
Documents
6
Period of Report
2025-02-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm252001-3_def14a.htm DEF 14A 899116
2 GRAPHIC lg_cyclacel-4c.jpg GRAPHIC 19400
3 GRAPHIC lg_secretarysoffistamp-bwlr.jpg GRAPHIC 13622
4 GRAPHIC px_cyclacel25pg01-4c.jpg GRAPHIC 299383
5 GRAPHIC px_cyclacel25pg02-4c.jpg GRAPHIC 226267
6 GRAPHIC sg_jeffreywbullock-bw.jpg GRAPHIC 10632
  Complete submission text file 0001104659-25-004635.txt   1653449
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 25540242
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)